Ardelyx is focused on enhancing the care and well-being of underserved patients with gastrointestinal and cardiorenal diseases by using the gut as the gateway to developing high-quality therapeutics. Ardelyx has pioneered the development of small molecule therapeutics that act predominantly in the GI tract, thereby avoiding potential negative side effects on the rest of the body. Ardelyx’s platform integrates technology that emulates the human GI tract with its gut-restricted chemistry capabilities, allowing for the development of optimized small molecules in a rapid and cost-efficient manner.